Lucy Godley

Professor

Office address: MC 2115
Telephone number: 773 702 4140; Pager 773 753 1880, 5141

Dr. Lucy Godley is an expert in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas, and multiple myeloma. She also cares for patients undergoing stem cell transplantation and patients with benign hematologic conditions.

Dr. Godley has a special interest in the molecular basis of bone marrow malignancies and is an active researcher in the field. In her laboratory, Dr. Godley studies the basis for cancer cells' abnormal patterns of DNA methylation, as well as inherited forms of bone marrow cancers.

She has received numerous awards for her research, including the Howard Hughes Medical Institute Physician Postdoctoral Award, the Cancer and Leukemia Group B (CALGB) Foundation Clinical Research Award, the American Society of Clinical Oncology Young Investigator Award, the Cancer Research Foundation Young Investigator Award, the Schweppe Foundation Career Development Award and the Kimmel Scholar Award. She was inducted into the American Society of Clinical Investigation in 2012.

Dr. Godley's goal is to improve health through a deeper understanding and appreciation of science by integrating knowledge about fundamental networks within cancer cells and by bringing novel insights into the pathophysiology of her patients' diseases while offering them new treatment options.

PUBLICATIONS

Peer-Reviewed Publications

1.       Godley, L.A., Pfeifer, J., Steinhauer, D., Ely, B., Shaw, G., Kaufmann, R., Suchanek, E., Pabo, C., Skehel, J.J., and Wiley, D.C.  Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity.  Cell 68:  635-645 (1992).

 

2.       Varmus, H.E., Godley, L.A., Roy, S., Taylor, I.C.A., Yuschenkoff, L., Shi, Y.-P., Pinkel, D., Gray, J., Pyle, R., Aldaz, C.M., Bradley, A., Medina, D., and Donehower, L.A.  Defining the steps in a multistep mouse model for mammary carcinogenesis.  Cold Spring Harb Symp Quant Biol. Volume LIX, 491-499 (1994).

 

3.       Donehower, L.A., Godley, L.A., Aldaz, C.M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H.E.  Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.  Genes Dev.  9: 882-895 (1995).

 

4.       Donehower, L.A., Godley, L.A., Aldaz, C.M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H.E.  The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model.  Prog. Clin. Biol. Res. 395: 1-11 (1996).

 

5.       Godley, L.A., Kopp, J.B., Eckhaus, M., Paglino, J.J., Owens, J., and Varmus, H.E.  Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys.  Genes Dev. 10: 836-850 (1996).

 

6.       Broccoli, D., Godley, L.A., Donehower, L.A., Varmus, H.E., and de Lange, T. Telomerase activation in mouse mammary tumors: Lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation.  Mol. Cell. Biol. 16: 3765-3772 (1996).

 

7.       Jones, J.M., Attardi, L., Godley, L.A., Laucirica, R., Medina, D., Jacks, T., Varmus, H.E., and Donehower, L.A.  Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.  Cell Growth and Diff. 8: 829-838 (1997).

 

8.       Godley, L.A., Lai, F., Liu, J., Zhao, N., and Le Beau, M.M.  TTID:  A novel gene at 5q31 encoding a protein with titin-like features.  Genomics.  60: 226-233 (1999).

 

9.       Lai, F., Orelli, B.J., Till, B.G., Godley, L.A., Fernald, A.A., Pamintuan, L., and Le Beau, M.M. Molecular characterization of KLHL3, a human homologue of the Drosophila kelch gene. Genomics.  66: 65-75 (2000).

 

10.    Lai, F., Godley, L.A., Fernald, A.A., Orelli, B.J., Pamintuan, L., Zhao, N., and Le Beau, M.M.  cDNA cloning and genomic structure of three genes localized to human chromosome band 5q31 encoding novel nuclear proteins.  Genomics.  70: 123-130 (2000).

 

11.    Lai, F., Godley, L.A., Joslin, J., Fernald, A.A., Liu, J., Espinosa III, R., Zhao, N., Pamintuan, L., Till, B.G., Larson, R.A., Qian, Z., and Le Beau, M.M.  Transcript map and comparative

analysis of the 1.5 Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).  Genomics. 71: 235-245 (2001).

 

12.    Qian, Z., Fernald, A.A., Godley, L.A., Larson, R.A., and Le Beau, M.M.  Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.  Proc. Natl. Acad. Sci. USA, 99: 14925-14930 (2002).

 

13.    van Besien, K., Artz, A., Smith, S., Cao, D., Rich, S., Godley, L., Jones, D., Del Cerro, P., Bennett, D., Casey, B., Odenike, O., Thirman, M., Daugherty, C., Wickrema, A., Zimmerman, T., Larson, R.A., and Stock, W.  Fludarabine, melphalan, and alemtuzumab conditioning in adults with advanced acute myeloid leukemia and myelodysplastic syndrome:  excellent outcomes in patients with standard-risk disease.  J. Clin. Oncol. 23: 5728-5738 (2005).

 

14.    Kline, J., Pollyea, D.A., Stock, W., Artz, A., Rich, E., Godley, L., Zimmerman, T., Thompson, K., Pursell, K., Larson, R.A., and van Besien, K.  Pre-transplant Ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab based conditioning.  Bone Marrow Transpl., 37(3): 307-310 (2006).

 

15.  Artz, A., Pollyea, D.A., Kocherginsky, M., Stock, W., Rich, E., Odenike, O., Zimmerman, T., Smith, S., Godley, L., Thirman, M., Daugherty, C., Extermann, M., Larson, R., and van Besien, K.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.  Biol Bone Marrow Transplant 12: 954-964 (2006).

 

16.    Ostler, K.R., Davis, E.M., Payne, S.L., Patel, B.B., Exposito-Cespedes, J., Le Beau, M.M., and Godley, L.A.  Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins.  Oncogene 26: 5553-5563 (2007).

 

17.    Pollyea, D.A., Artz, A.S., Stock, W., Daugherty, C., Godley, L., Odenike, O.M., Rich, E., Smith, S.M., Zimmerman, T., Zhang, Y., Huo, D., Larson, R., and van Besien, K.  Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.  Bone Marrow Transplant. 40: 1027-1032 (2007).

 

18.    Hill, B.T., Kondapalli, L., Artz, A., Smith, S.M., Rich, E., Godley, L., Odenike, O., Pursell, K.J., Larson, R.A., Stock, W., and van Besien, K.  Successful allogeneic transplantation of patients with suspected prior invasive mold infection.  Leuk Lymphoma 48: 1799-1805 (2007).

 

19.    Gordon, M.K., Sher, D., Karrison, T., Kebriaei, P., Chuang, K., Zhang, Y., McDonnell, D., Artz, A., Godley, L., Odenike, O., Rich, E., Michaelis, L., Thirman, M.J., Wickrema, A., van Besien, K., Larson, R.A., and Stock, W.  Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow and apheresis products.  Leuk Lymphoma 49: 531-537 (2008).

 

20.    Klisovic, R.B., Stock, W., Cataland, S., Klisovic, M.I., Liu, S., Blum, W., Green, M., Odenike, O., Godley, L., Burgt, J.V., Van Laar, E., Cullen, M., Macleod, A.R., Besterman, J.M., Reid, G.K., Byrd, J.C., and Marcucci, G.  A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferases 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.  Clin Cancer Res 14(8): 2444-2449 (2008).

 

21.    Stock, W., Undevia, S.D., Bivins, C., Ravandi, F., Odenike, O., Faderl, S., Rich, E., Borthakur, G., Godley, L., Verstovsek, S., Artz, A., Wierda, W., Larson, R.A., Zhang, Y., Cortes, J., Ratain, M.J., and Giles, F.J.  A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.  Invest New Drugs 26: 331-338 (2008).

 

22.    Ozer, O., Zhao, Y.D., Ostler, K.R., Akin, C., Anastasi, J., Vardiman, J.W., and Godley, L.A.  The

identification and characterization of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells.  Leuk Lymphoma 49: 1567-1577 (2008).

 

23.    Carbonaro, A., Mohanty, S.K., Huang, H., Godley, L.A., and Sohn, L.L. NanoCytometry:  A label-free technique for performing single-cell screening.  Lab Chip 8: 1478-1485 (2008).

 

24.     Artz, A.S., Wickrema, A., Dinner, S., Godley, L.A., Kocherginsky, M., Odenike, O., Rich, E.S., Stock, W., Ulaszek, J., Larson, R.A., and van Besien, K.  Pre-treatment C-reactive protein (CRP) is a predictor for outcomes after reduced intensity allogeneic hematopoietic cell transplantation.  Biol Bone Marrow Transpl. 14: 1209-1216 (2008).

 

25.     Poiré, X., Artz, A., Larson, R.A., Kline, J., Odenike, O., Rich, E., Godley, L., Stock, W., van Besien, K.  Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.  Leuk Lymphoma 50: 85-91 (2009).

 

26.     Zhou, Y., Goodenbour, J.M., Godley, L.A., Wickrema, A., and Pan, T.  High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.  Biochem. Biophys. Res. Comm. 385: 160-164 (2009).

 

27.     Steensma, D.P., Baer, M., Slack, J., Buckstein, R., Godley, L.A., Garcia-Manero, G., Albitar, M., Larsen, J.S., Arora, S., Cullen, M., and Kantarjian, H.M.  Multi-center study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The ADOPT (alternative dosing for outpatient treatment) Trial.  J Clin. Oncol. 27: 3842-3848 (2009).

 

28.     van Besien, K., Dew, A., Lin, S., Joseph, L., Godley, L.A., Larson, R.A., Odenike, O., Rich, E., Stock, W., Wickrema, A., and Artz, A.  Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.  Leuk Lymphoma 50: 1809-1817 (2009).

 

29.      Godley, L.A., Njiaju, U.O., Green, M., Weiner, H., Lin, S., Odenike, O., Stock, W., Rich, E.S., Artz, A., van Besien, K., Daugherty, C.K., White, C., Ridgeway, J., Zhang, Y., Le Beau, M.M., and Larson, R.A., Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantation.  Leuk Lymphoma 51: 995-1006 (2010).

 

30.      Shah, M.Y., Vasanthakumar, A., Barnes, N.Y., Figueroa, M.E., Kamp, A., Hendrick, C., Ostler, K.R., Davis, E.M., Lin, S., Anastasi, J., Le Beau, M.M., Moskowitz, I., Melnick, A., Pytel, P., and Godley, L.A. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Research 70: 5840-5850 (2010).

 

31.      Yang, Q., Tian, Y., Ostler, K.R., Chlenski, A., Guerrero, L., Salwen, H.R., Godley, L.A., and Cohn, S.L.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.  BioMed Central Cancer 10: 286-296 (2010).

 

32.      Churpek, J.E., Garcia, J.S., Madzo, J., Jackson, S., Onel, K., and Godley, L.A. Identification and molecular characterization of a novel 3’ mutation in RUNX1 in a family with Familial Platelet Disorder. Leuk Lymphoma 51: 1931-1935 (2010).

 

33.      Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J.M., Thompson, C.B., Levine, R.L., and Melnick, A.  IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.  Cancer Cell 18: 553-567 (2010).

 

34.      O’Donnell, P.H., Artz, A.S., Undevia, S.D., Pai, R.K., del Cerro, P., Horowitz, S. Godley, L.A., Hart, J., Innocenti, F., Larson, R.A., Odenike, O.M., Stock, W., and van Besien, K.  Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation.  Reduced clearance at high doses and occurrence of late SOS/VOD. Leuk Lymphoma 51: 2240-2249 (2010). 

 

35.      Song, C.-X., Szulwach, K.E., Fu, Y., Dai, Q., Yi, C., Li, X., Chen, C.-H., Zhang, W., Jian, X., Wang, J., Zhang, L., Looney, T.J., Zhang, B., Godley, L.A., Hicks, L.M., Lahn, B.T., and He, C. Selective labeling of 5-hydroxymethylcytosine in genomic DNA from cell lines and murine tissues.  Nature Biotech 29: 68-72 (2011).

 

36.      Kenkre, V.P., Horowitz, S., Artz, A.S., Liao, C., Cohen, K.S., Godley, L.A., Kline, J.P., Smith, S.M., Stock, W., van Besien, K.  Alemtuzumab-containing conditioning for allogeneic transplant (HCT) in lymphoma: Predictors of outcome.  Leuk Lymphoma 52: 214-222 (2011).

 

37.      Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., Godley, L.A., Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Jedrzejczak, W.W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Bensen-Kennedy, D.M., Small, D., and Smith, B.D. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.  Blood 117: 3294-3301 (2011).

 

38.      Woloszynska-Read, A., Zhang, W., Yu, J., Link, P.A., Mhawech-Fauceglia, P., Collamat, G., Akers, S.N., Ostler, K.R., Godley, L.A., Odunsi, K., and Karpf, A.R.  Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with BORIS/CTCF mRNA expression ratio.  Clin Cancer Res 17: 2170-2180 (2011).

 

39.      Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadil, J., Nimer, S., Melnick, A., Godley, L. A., Aifantis, I., and Levine, R. L.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.  Cancer Cell 20: 11-24 (2011).

 

40.      Quivoron, C., Couronné, L., Della Valle, Véronique, Lopez, C., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., Godley, L., Opolon, P., Tilly, H., Solary, E., Duffourd, Y., Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T., and Bernard, O. A. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.  Cancer Cell 20: 25-38 (2011).

 

41.      Pronier, E., Almire, C., Mokrani, H., Vasanthakumar, A., Simon, A., da Costa Reis Monte Mor, B., Masse, A., Le Couedic, J.-P., Pendino, F., Carbonne, B., Larghero, J., Ravanat, J.-L., Casadevall, N., Bernard, O.A., Droin, N., Solary, E., Godley, L.A., Vainchenker, W., Plo, I., and Delhommeau, F.  Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors.  Blood 118: 2551-2555 (2011).

 

42.      Shaknovich, R., Cerchietti, L., Tsikitas, L., Kormaksson, M., De, S., Figueroa, M.E., Ballon, G., Yang, S.N., Weinhold, N., Reimers, M., Clozel, T., Luttrop, K., Ekstrom, T.J., Frank, J., Vasanthakumar, A., Godley, L.A., Michor, F., Elemento, O., and Melnick, A.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.  Blood 118: 3559-3569 (2011).

 

43.      Liu, H., Rich, E.S., Godley, L., Odenike, O., Joseph, L., Marino, S., Kline, J., Nguyen, V., Cunningham, J., Larson, R.A., del Cerro, P., Schroeder, L., Pape, L., Stock, W., Wickrema, A., Artz, A.S., and van Besien, K.  Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 118: 6438-6445 (2011).

 

44.      Szulwach, K.E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., Irier, H., Upadhyay, A.K., Gearing, M., Levey, A.I., Vasanthakumar, A., Godley, L.A., Chang, Q., Cheng, X., He, C., and Jin, P.  5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14: 1607-1616 (2011).

 

45.      Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.-P. J., Godley, L.A., Li, W., and Goodell, M.A. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics 44: 23-31 (2011).

 

46.      van Besien, K., Stock, W., Rich, E., Odenike, O., Godley, L., O’Donnell, P.H., Kline, J., Nguyen, V., Larson, R., and Artz, A.  Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.  Biol Bone Marrow Transpl. 18: 913-921 (2012).

 

47.      Doçi, C.L., Mankame, T.P., Langerman, A., Ostler, K.R., Kanteti, R., Best, T., Onel, K., Godley, L.A., Salgia, R., and Lingen, M.W.  Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.  Int J Gynecol Pathol 31:15-24 (2012).

 

48.      Larson, S.M., Campbell, N.P., Huo, D., Artz, A., Zhang, Y., Gajria, D., Green, M., Weiner, H., Daugherty, C., Odenike, O., Godley, L.A., Hyjek, E., Gurbuxani, S., Thirman, M., Sipkins, D., van Besien, K., Larson, R.A., and Stock, W.  High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma 53: 445-450 (2012).

 

49.      Yamazaki, J., Taby, R., Vasanthakumar, A., Macrae, T., Ostler, K.R., Shen, L., Kantarjian, H.M., Estecio, M.R., Jelinek, J., Godley, L.A., and Issa, J.-P.J.  Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.  Epigenetics 7: 201-207 (2012).

 

50.      Nanduri, J., Makarenko, V., Reddy, V.D., Yuan, G., Pawar, A., Wang, N., Khan, S.A., Zhang, X., Kinsman, B., Peng, Y.J., Kumar, G.K., Fox, A.P., Godley, L.A., Semenza, G.L., and Prabhakar, N.R.  Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis.  Proc Natl Acad Sci USA 109: 2515-2520 (2012).

 

51.      Richa, E.M., Kunnavakkam, R., Godley, L.A., Kline, J., Odenike, O., Larson, R.A., Nguyen, V., Stock, W., Wickrema, A., van Besien, K., Artz, A.  Influence of related donor age on outcomes after peripheral blood stem cell transplantation.  Cytotherapy 14: 707-715 (2012).

 

52.      Ostler, K.R., Yang, Q., Looney, T.J., Zhang, L., Vasanthakumar, A., Tian, Y., Kocherginsky, M., Raimondi, S.L., DeMaio, J.G., Salwen, H.R., Gu, S., Chlenski, A., Naranjo, A., Gill, A., Peddinti, R., Lahn, B.T., Cohn, S.L., and Godley, L.A. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma.  Cancer Research 72: 4714-4723 (2012).

 

53.      Busque, L., Patel, J.P., Figueroa, M., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., Hassimi, M., Socci, N., Bhatt, P.K., Gonen, M., Mason, C.E., Melnick , A., Godley, L.A., Brennan, C., Abdel-Wahab, O., and Levine, R.L.  Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.  Nature Genetics 44: 1179-1181 (2012).

 

54.      Churpek, J.E., Nickels, E., Marquez, R., Rojek, K., Liu, B., Lorenz, R., Lepore, J., Madzo, J., Wickrema, A., Artz, A., van Besien, K., and Godley, L.A.  Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplant donors with thrombocytopenia.  Blood 120: 5247-5249 (2012).

 

55.      Churpek, J.E., Lorenz, R., Nedumgottil, S., Onel, K., Olopade, O., Sorrell, A., Owen, C.J., Bertuch, A.A., and Godley, L.A.  A proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes.  Leuk Lymphoma 54: 28-35 (2013).

 

56.      Pollyea, D.A., Kohrt, H.E., Zhang, B., Zehnder, J., Schenkein, D., Fantin, V., Straley, K., Vasanthakumar, A., Abdel-Wahab, O., Levine, R., Godley, L.A., and Medeiros, B.C.  2-Hydroxyglutarate in IDH mutant AML:  Predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma 54: 408-410 (2013).

 

57.      Vasanthakumar, A., Lepore, J.B., Zegarek, M.H., Kocherginsky, M., Singh, M., Davis, E.M., Link, P.A., Anastasi, J., Le Beau, M.M., Karpf, A.R., and Godley, L.A.  Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis.  Blood 121: 2059-2063 (2013).

 

58.      Yu, Y., Mo, Y., Ebenezer, D., Bhattacharyya, S., Liu, H., Sundaravel, S., Wonkatal, S., Cartier, J., Caces, B., Artz, A., Nischal, S., Bhagat, T., Bathon, K., Maqbool, S., Gligich, O., Suzuki, M., Steidl, U., Godley, L., Skoultchi, A., Greally, J., Wickrema, A., and Verma, A. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. J Biol Chem. 288: 8805-8814 (2013).

 

59.      Lu, Z., Tian, Y., Salwen, H.R., Chlenski, A., Godley, L.A., Raj, J.U., and Yang, Q.  Histone lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.  Anti-Cancer Drugs 24: 484-493 (2013).

 

60.      Jain, N., Artz, A., Anastasi, J., Odenike, O., Godley, L.A., Joseph, L., Marino, S., Kline, J., Nguyen, V., Schouten, V., Kunnavakkam, R., Larson, R.A., Stock, W., Ulaszek, J., Savage, P.A., Wickrema, A., and van Besien, K.  Immune reconstitution after combined haploidentical and umbilical cord blood transplant.  Leuk Lymphoma 54: 1242-1249 (2013).

 

61.      Garcia-Manero, G.,  Jabbour, E., Borthakur, G., Faderl, S., Estrov, Z., Yang, H., Maddipoti, S., Godley, L.A., Gabrail, N., Berdeja, J.G., Nadeem, A., Kassalow, L., and Kantarjian, H. Randomized open-label Phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.  J. Clin. Oncol. 31: 2548-2553 (2013).

 

62.      Locke, F., Agarwal, R., Kunnavakkam, R., van Besien, K., Larson, R.A., Odenike, O., Godley, L.A., Liu, H., Le Beau, M.M., Gurbuxani, S., Thirman, M.J., Sipkins, D., White, C., Artz, A., Stock, W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 48: 1437-1443 (2013). 

 

63.      Moen, E.L., Zhang, X., Mu, W., Delaney, S.M., Wing, C., McQuade, J., Myers, J., Godley, L.A., Dolan, M.E., and Zhang, W. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits.  Genetics 194: 987-996 (2013).

 

64.      Clozel, T., Yang, S., Elstrom, R., Tam, W., Kormaksson, M., Banerjee, S., Vasanthakumar, A., Culjkovic, B., Scott, D., Ammerpohl, O., Brennan, S., Leser, M., Martin, P., Borden, K., Shaknovich, R., Siebert, R., Chadburn, A., Godley, L.A., Gascoyne, R., Leonard, J.P., Melnick, A., and Cerchietti, L. SMAD1 demethylation contributes to epigenetic chemosensitization of human diffuse large B cell lymphoma Cancer Discov 3: 1-18 (2013).

 

65.      Bhattacharyya, S., Yu, Y., Suzuki, M., Campbell, N., Mazdo, J., Vasanthakumar, A., Bhagat, T.D., Nischal, S., Christopeit, M., Parekh, S., Steidl, U., Godley, L., Maitra, A., Greally, J.M., and Verma, A.  Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.  Nucl. Acids Res. 41: e157 (2013).

 

66.      Jeong, M., Sun, D., Luo, M., Huang, Y., Challen, G.A., Rodriguez, B., Zhang, X., Chavez, L., Wang, H., Hannah, R., Kim, S.B., Yang, L., Ko, M., Chen, R., Göttgens, B., Lee, J.S., Gunaratne, P., Godley, L.A., Darlington, G.J., Rao, A., Li, W., and Goodell, M.A.  Large conserved domains of low DNA methylation maintained by Dnmt3a.   Nature Genetics 46: 17-23 (2014).

 

67.      Madzo, J., Liu, H., Rodriguez, A., Vasanthakumar, A., Sundaravel, S., Caces, D.B., Looney, T.J., Zhang, L., Lepore, J.B., Macrae, T., Duszynski, R., Shih, A.H., Song, C.X., Yu, M., Yu, Y., Grossman, R., Raumann, B., Verma, A., He, C., Levine, R.L., Lavelle, D., Lahn, B.T., Wickrema, A., and Godley, L.A.  Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.  Cell Rep. 6: 231-244 (2014).

 

68.      Chambwe, N., Kormaksson, M., Geng, H., De, S., Michor, F., Johnson, N.A., Morin, R.D., Scott, D.W., Godley, L.A., Gascoyne, R.D., Melnick, A., Campagne, F., and Shaknovich, R.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.  Blood 123: 1699-1708 (2014).

 

69.      Moen, E.L., Stark, A.L., Zhang, W., Dolan, M.E., and Godley, L.A. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.  Mol Cancer Ther. 13: 1334-1344 (2014).

 

70.      Mariani, C.J., Vasanthakumar, A., Madzo, J., Yesilkanal, A., Bhagat, T., Yu, Y., Bhattacharyya, S., Wenger, R.H., Cohn, S.L., Nanduri, J., Verma, A., Prabhakar, N.R., and Godley, L.A.  TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma.  Cell Rep. 7:1343-52 (2014).

 

71.      Muffly, L.S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M.R., Godley, L.A., Kline, J., Liu, H., Odenike, O.M., Larson, R.A., van Besien, K., and Artz, A.S. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.  Haematologica 99: 1373-1379 (2014).

 

72.      Ustun, C., Reiter, A., Scott, B.L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W.J., Perales, M.A., Shore, T., Baurmann, H., Stuart, R., Gruhn, B., Doubek, M., Hsu, J.W., Tholouli, E., Gromke, T., Godley, L.A., Pagano, L., Gilman, A., Wagner, E.M., Shwayder, T., Bornhäuser, M., Papadopoulos, E.B., Böhm, A., Vercellotti, G., Van Lint, M.T., Schmid, C., Rabitsch, W., Pullarkat, V., Legrand, F., Yakoub-Agha, I., Saber, W., Barrett, J., Hermine, O., Hagglund, H., Sperr, W.R., Popat, U., Alyea, E.P., Devine, S., Deeg, H.J., Weisdorf, D., Akin, C., and Valent, P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.  J Clin. Oncol. 32: 3264-3274 (2014).

 

73.      Zhang, X., Moen, E.L., Mu, W., Gamazon, E.R., Delaney, S.M., Wing, C., Godley, L.A., Dolan, M.E., and Zhang, W.  Linking the genetic architecture of cytosine modifications with human complex traits.  Human Molec Genet. 23: 5893-5905 (2014).

 

74.      Marquez, R., Hantel, A., Lorenz, R., Neistadt, B., Wong, J., Churpek, J.E., Al Mardini, N., Shaukat, I., Gurbuxani, S., Miller, J., and Godley, L.A.  A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies.  Leuk Lymphoma 55: 2945-2946 (2014).

 

75.      Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., Lu, C., Ward, P.S., Tsai, J.J., Hricik, T., Tosello, V., Tallman, J.E., Zhao, X., Daniels, D., Dai, Q., Ciminio, L., Aifantis, I., He, C., Fuks, F., Tallman, M.S., Ferrando, A., Carroll, M., Paietta, E., Thompson, C.B., Licht, J.D., Mason, C., Godley, L.A., Melnick, A., Figueroa, M.E., and Levine, R.L. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.  Cell Rep. 9: 1841-1855 (2014).

 

76.      Zhang, M.Y., Churpek, J.E., Keel, S.B., Walsh, T., Lee, M.K., Loeb, K.R., Gulsuner, S., Pritchard, C.C., Sanchez-Bonilla, M., Delrow, J.J., Basom, R.S., Forouhar, M., Gyurkocza, B., Schwartz, B.S., Neistadt, B., Marquez, R., Mariani, C., Coats, S., Hofmann, I., Lindsley, R.C., Williams, D.A., Abkowitz, J.L., Horwitz, M.S., King, M.-C., Godley, L.A., and Shimamura, A.  Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.  Nature Genetics 47: 180-185 (2015).

 

77.      Odenike, O., Halpern, A., Godley, L.A., Mado, J., Karrison, T., Green, M., Fulton, N., Mattison, R.J., Yee, K.W., Bennett, M., Koval, G., Malnassy, G., Larson, R.A., Ratain, M.J., and Stick, W.  A phase I and pharmacodynamics study of the histone deacetylase inhinitor belinostat plus Azacitidine in advanced myeloid neoplasia.  Invest New Drugs 33: 371-379 (2015).

 

78.      Brambert, P.R., Kelpsch, D.J., Hameed, R., Desai, C.V., Calafiore, G., Godley, L.A., and Raimondi, S.L. DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells.  PLos One. 10: e0117310.

 

79.      Balakrishan, K.R., Whang, J.C., Hwang, R., Hack, J.H., Godley, L.A., and Sohn, L.L. Node-pore sensing enables label-free surface-marker profiling of single cells.  Analytical Chem 87: 2988-2995 (2015).

 

80.      Polprasert, C., Schulze, I., Sekeres, M.A., Makishima, H., Przychodzen, B., Hosono, N., Singh, J., Padgett, R.A., Gu, X., Phillips, J.G., Clemente, M., Parker, V., Lindner, D., Dienes, B., Du, Y., Oakley, K., Nguyen, N., Mukherjee, S., Pabst, C., Godley, L.A., Churpek, J.E., Pollyea, D.A., Krug, U., Klein, H.-U.,  Dugas, M., Berdel, W., Yoshida, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Ogawa, S.,  Müller Tidow, C., and Maciejewski, J.P.  Inherited and somatic defects in DDX41 in myeloid neoplasms.  Cancer Cell 27: 658-670 (2015).

 

81.      Yamazaki, J., Jelinek, J., Lu, Y., Cesaroni, M., Madzo, J., Neumann, F., He, R., Taby, R., Vasanthakumar, A., Macrae, T., Ostler, K.R., Kantarjian, H.M., Liang, S., Estecio, M.R., Godley, L.A., and Issa, J.P. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia.  Can Res 75: 2833-2843 (2015).

 

82.      Moen, E.L., Litwin, E., Arnovitz, S., Zhang, X., Zhang, W., Dolan, M.E., and Godley, L.A.  Characterization of CpG sites that escape methylation on the inactive human X-chromosome.  Epigenetics 10: 810-818 (2015).

 

83.      Dominguez, P.M., Teater, M., Chambwe, N., Kormaksson, M., Redmond, D., Ishii, J., Vuong, B., Chaudhuri, J., Melnick, A., Vasanthakumar, A., Godley, L.A., Papavasiliou, F.N., Elemento, O., and Shaknovich, R. DNA methylation dynamics of germinal center B cells are mediated by AID.  Cell Rep 12: 2086-2098 (2015)

 

84.      Churpek, J.E., Pyrtel, K., Kanchi, K.L., Shao, J., Koboldt, D., Miller, C.A., Shen, D., Fulton, R., O’Laughlin, M., Fronick, C., Pusic, I., Uy, G.L., Braunstein, E.M., Levis, M., Ross, J., Elliott, K., Heath, S., Jiang, A., Westervelt, P., DiPersio, J.F., Link, D.C., Walter, M.J., Welch, J., Wilson, R., Ley, T.J., Godley, L.A., and Graubert, T.A. Genomic analysis of germline and somatic variants in familial myelodysplasia/acute myeloid leukemia.  Blood 126: 2484-2490 (2015).

 

85.      Chapman, C.G., Mariani, C.J., Wu, F., Meckel, K., Butun, F., Chuang, A., Madzo, J., Bissonnette, M.B., Kwon, J.H., and Godley, L.A.  TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiatin colonocytes and colon cancer.  Sci. Rep. 5: 17568 (2015).

 

86.      Vasanthakumar, A., Zullow, H., Lepore, J.B., Thomas, K., Young, N., Anastasi, J., Reardon, C.A., and Godley, L.A. Epigenetic control of Apolipoprotein E expression mediates gender-specific hematopoietic regulation.  Stem Cells 33: 3643-3654 (2015).

 

87.      Churpek, J.E., Marquez, R., Neistadt, B., Claussen, K., Lee, M.K., Churpek, M.M., Huo, D., Weiner, H., Bannerjee, M., Godley, L.A., Le Beau, M.M., Pritchard, C.C., Walsh, T., King, M.C., Olopade, O,I., and Larson, R.A. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122: 304-311 (2016).

 

88.      Churpek, J.E., Artz, A., Bishop, M., Liu, H., and Godley, L.A. Correspondence regarding the consensus statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.  Biol Blood Marrow Transplant. 22: 183-184 (2016).

 

89.      Vasanthakumar, A., Arnovitz, S., Marquez, R., Lepore, J., Rafidi, G., Asom, A., Weatherly, M., Davis, E.M., Neistadt, B., Duszynski, R., Vardiman, J.W., Le Beau, M.M., Godley, L.A., and Churpek, J.E. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice.  Blood 127: 310-313 (2016).

 

90.      Lewinsohn, M., Brown, A.L., Weinel, L.M., Phung, C., Rafidi, G., Lee, M.K., Schreiber, A.W., Feng, J., Babic, M., Chong, C.E., Lee, Y., Yong, A., Suthers, G.K., Poplawski, N., Altree, M., Phillips, K., Jaensch, L., Fine, M., D'Andrea, R.J., Lewis, I.D., Medeiros, B.C., Pollyea, D.A., King, M.C., Walsh, T., Keel, S., Shimamura, A., Godley, L.A., Hahn, C.N., Churpek, J.E., and Scott, H.S. Novel germline DDX41 mutations define families with lower age of MDS/AML onset and lymphoid malignancies.  Blood 127: 1017-1023 (2016).

 

91.      Laukka, T., Mariani, C.J., Ihantola, T., Cao, J.Z., Hokkanen, J., Kaelin, W.G. Jr, Godley, L.A., and Koivunen, P. Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes.  J Biol Chem 291: 4256-4265 (2016).

 

92.      Schulze, I., Rohde, C., Scheller-Wendorff, M., Krause, A., Herbst, F., Riemke, P., Hebestreit, K., Tschanter, P., Lin, Q., Linhart, H., Godley, L.A., Glimm, H., Dugas, M., Wagner, W., Berdel, W.E., Rosenbauer, F., and Müller-Tidow, C. Increased DNA methylation of Dnmt3b-targets impairs leukemogenesis.  Blood 127: 1575-1586 (2016).

 

93.      D'Angelo, C.R., Kocherginsky, M., Pisano, J., Bishop, M.R., Godley, L.A., Kline, J., Larson, R.A., Liu, H., Odenike, O., Stock, W., and Artz, A.S. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.  Leuk Lymphoma 57: 1807-1813 (2016).

 

94.      Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M.R., Sekeres, M.A., Roboz, G.J., Gaidano, G., Scott, B.L., Greenberg, P., Platzbecker, U., Steensma, D.P., Kambhampati, S., Kreuzer, K.A., Godley, L.A., Atallah, E., Collins, R. Jr., Kantarjian, H., Jabbour, E., Wilhelm, F.E., Azarnia, N., Silverman, L.R., and ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.  Lancet Oncol. 17: 496-508 (2016).

 

95.      DiNardo, C.D., Bannon, S.A., Routbort, M., Franklin, A., Mork, M., Armanios, M., Mace, E.M., Orange, J.S., Jeff-Eke, M., Churpek, J.E., Takahashi, K., Jorgensen, J.L., Garcia-Manero, G., Kornblau, S., Bertuch, A., Cheung, H., Bhalla, K., Futreal, A., Godley, L.A., and Patel, K.P. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC).  Clin Lymphoma Myeloma Leuk 16: 417-428.e2. (2016).

 

96.      Rojek, K., Nickels, E., Neistadt, B., Marquez, R., Wickrema, A., Artz, A., van Besien, K., Larson, R.A., Lee, M.K., Segal, J.P., King, M.-C., Walsh, T., Shimamura, A., Keel, S.B., Churpek, J.E., and Godley, L.A. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy.  Biol Blood Marrow Transplant. 22: 2100-2103 (2016).

 

97.      Applebaum, M.A., Jha, A.R., Kao, C., Hernandez, K.M., DeWane, G., Salwen, H.R., Chlenski, A., Dobratic, M., Mariani, C.J., Godley, L.A., Prabhakar, N., White, K., Stranger, B.E., and Cohn, S.L. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.  Oncotarget epub (2016).